Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Youdom, Solange Whegang ^a,b,c,d   Samson, Adeline ^b   Basco, Leonardo K ^c,d   Thalabard, Jean Christophe ^b,e  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Laboratoire de Recherche sur le Paludisme Yaounde   (Cameroon)

^e HÔTEL DIEU   (France)

Author keywords

Bayesian approach; Drug resistance; Mixed models; Mixed treatment comparisons; Ordinal data; Plasmodium falciparum

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ARTICLE; BAYES THEOREM; CHILD; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; FEVER; GENDER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITEMIA; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIMALARIALS; CAMEROON; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; TREATMENT OUTCOME;

EID: 84869218551     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-147     Document Type: Article

References (39)

1. World malaria report 2008. WHO, 2008 http://www.who/int/malaria/wmr2008/ MAL2008-SumKey-EN.pdf
2. Artemisinin resistance: current status and scenarios for containment. Dondorp A, Yeung S, White L, Nguon C, Day N, Socheat D, von Seidlein L, Nat Rev Microbiol 2010 8 272 280 20208550
3. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria Geneva: World Health Organization. WHO, Tech rep 2003
4. Agresti A, Categorical Data Analysis, (2nd edn) New Jersey: Wiley 2002
5. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Whegang S, Tahar R, Foumane VN, Soula G, Gwèt H, Thalabard J, Basco L, Malar J 2010 9 56 10.1186/1475-2875-9-56 20170477
6. Analysis of an ordinal outcome in a multicentric randomized controlled trial: application to a 3- arm anti malarial drug trial in Cameroon. Whegang S, Basco L, Gwèt H, Thalabard J, BMC Med Res Methodol 2010 10 58 10.1186/1471-2288-10-58 20565837
7. Meta-analysis of multitreatment studies. Hasselblad V, Med Decis Making 1998 18 37 43 10.1177/0272989X9801800110 9456207 (Pubitemid 28041639)
8. A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence. Ades A, Stat Med 2003 22 2995 3016 10.1002/sim.1566 12973783 (Pubitemid 37160601)
9. Meta-analysis of mixed treatment comparisons at multiple follow-up times. Lu G, Ades A, Sutton A, Cooper NJ, Briggs AH, Caldwell DM, Stat Med 2007 26 3681 3699 10.1002/sim.2831 17285571 (Pubitemid 47307743)
10. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Jansen J, Crawford B, Bergman G, Stam W, Value Health 2008 11 956 964 10.1111/j.1524-4733.2008.00347.x 18489499
11. Combination of direct and indirect evidence in mixed treatment comparisons. Lu G, Ades A, Stat Med 2004 23 3105 3124 10.1002/sim.1875 15449338 (Pubitemid 39334902)
12. Indirect comparisons of competing interventions. Glenny A, Altman DG, Song F, Sakarovitch C, Deeks JJ, DAmico R, Bradburn M, Eastwood AJ, Group ISTC, Health Technol Assess 2005 9 1 134 16303099
13. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Jansen J, Curr Med Res Opin 2006 22 671 681 10.1185/030079906X96308 16684428
14. Incorporating direct and indirect evidence using bayesian methods: an applied case study in ovarian cancer. Griffin S, Bojke L, Main C, Palmer S, Value Health 2006 9 123 131 10.1111/j.1524-4733.2006.00090.x 16626416 (Pubitemid 44044745)
15. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Caldwell D, Ades AE, Higgins JPT, BMJ 2005 331 897 900 10.1136/bmj.331.7521.897 16223826 (Pubitemid 41502718)
16. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996-2004. WHO, Tech rep 2005
17. Regression models for ordinal data. McCullagh P, J R Statist Soc 1980 42 109 142
18. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, et al. Malar J 2009 8 203 10.1186/1475-2875-8- 203 19698172
19. Modelling and estimating heterogeneous variances in threshold models for ordinal discrete data via Winbugs/Openbugs. Foulley J, Jaffrezic F, Comput Methods Programs Biomed 2010 24 19 27
20. WinBUGS- a Bayesian modelling framework: concepts, structure, and extensibility. Lunn D, Thomas A, Best N, Spiegelhalter D, Stat Comput 2000 10 325 337 10.1023/A:1008929526011
21. Bayesian measures of model complexity and fit (with discussion). Spiegelhalter D, Best N, Carlin B, van der Linde A, J R Stat Soc B 2002 64 583 640 10.1111/1467-9868.00353
22. Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis. Jansen F, Lesaffre E, Penali L, Garcia-Zattera M, Die-Kakou H, Bissagnene E, Am J Trop Med Hyg 2007 27 1703 1717
23. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Dakin HA, JWelton N, Ades AE, Collins S, Ormec M, Kelly S, Stat Med 2011 20 2511 2535
24. Rapport 2009 sur le paludisme dans le monde. WHO, Tech rep 2009
25. Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. Song F, Harvey I, Lilford R, J Clin Epidemiol 2008 61 455 463 10.1016/j.jclinepi.2007.06.006 18394538 (Pubitemid 351446184)
26. Inference and missing data. Rubin D, Biometrika 1976 5 581 592
27. The analysis of ordered categorical data: an overview and a survey of recent developments. Liu Y, Agresti A, Societas de Estadistica e Investigacion Operativa 2005 24 1 73 (Pubitemid 41017427)
28. A randomized trial of artemether-lumefantrine versus mefloquine- artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Hutagalung R, Paiphun L, Ashley E, McGready R, Brockman A, Thwai K, Singhasivanon P, Jelinek T, White N, Nosten F, Malar J 2005 4 46 10.1186/1475-2875-4-46 16179089 (Pubitemid 41455936)
29. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, Ezedinachi E, Malar J 2006 5 43 10.1186/1475-2875-5-43 16704735 (Pubitemid 43865102)
30. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Guthmann J, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noel F, Mulemba M, Balkan S, Am J Trop Med Hyg 2006 75 143 145 16837721 (Pubitemid 351627583)
31. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Smithuis F, Kyaw MK, Phe O, Aye K, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White N, Lancet 2006 367 2075 2085 10.1016/S0140-6736(06)68931-9 16798391 (Pubitemid 43949291)
32. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Hasugian A, Purba H, Kenangalem E, Wuwung RM, Ebsworth EP, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN, Maristela, R, Clin Infect Dis 2007 44 1067 1074 10.1086/512677 17366451 (Pubitemid 46580274)
33. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. Yeka A, Dorsey G, Kamya M, Talisuna A, Lugemwa M, Rwakimari J, Rosenthal P, Wabwire-Mangen F, Bukirwa H, Staedke, S, PLoS One 2008 3 2390 10.1371/journal.pone.0002390 18545692
34. A randomized trial of artesunate-mefloquine versus artemether- lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara S, Guindo O, Maiga H, Niambele M, Sissoko M, Dicko A, Djimde A, Doumbo O, Am J Trop Med Hyg 2008 79 655 661 18981499
35. A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya. Mens P, Sawa P, van Amsterdam S, Versteeg I, Omar S, Schallig H, Kager P, Malar J 2008 7 237 10.1186/1475-2875-7-237 19017387
36. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G, Kamya, M R, Clin Infect Dis 2009 49 1629 1637 10.1086/647946 19877969
37. Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, Mali. Kayentao K, Maiga H, Newman R, McMorrow M, Hoppe A, Yattara O, Traore H, Kone Y, Guirou E, Saye R, Traore B, Djimde A, Doumbo O, Malar J 2009 8 5 10.1186/1475-2875-8-5 19128455
38. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Faye B, Ndiaye J, Tine R, Sylla K, Gueye A, Colle A, Gaye O, Am J Trop Med Hyg 2010 82 140 144 10.4269/ajtmh.2010.09-0265 20065010
39. Artemisinin-based combination therapy for treating uncomplicated malaria. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P, Cochrane Database Syst Rev 2009 3 1 270